NEM vs SPRO · P/E 14, rev $13.43B vs P/E 9.6, rev $258.0K
Newmont Goldcorp Corp (NEM) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Latest reported SPRO revenue for 2026-06-30 was $258.0K. Net income was -$16.8M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
NEM currently screens at market cap $112.81B and trailing P/E 13.7. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the NEM and SPRO stock pages for the full models.
Not investment advice.